- Home
- IVCB vs BDSX Comparison
IVCB vs BDSX Comparison
Compare IVCB & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVCB
- BDSX
- Stock Information
- Founded
- IVCB 2021
- BDSX 2005
- Country
- IVCB Cayman Islands
- BDSX United States
- Employees
- IVCB N/A
- BDSX N/A
- Industry
- IVCB Blank Checks
- BDSX Precision Instruments
- Sector
- IVCB Finance
- BDSX Health Care
- Exchange
- IVCB Nasdaq
- BDSX Nasdaq
- Market Cap
- IVCB 212.7M
- BDSX 245.3M
- IPO Year
- IVCB 2021
- BDSX 2020
- Fundamental
- Price
- IVCB $11.80
- BDSX $1.63
- Analyst Decision
- IVCB
- BDSX Strong Buy
- Analyst Count
- IVCB 0
- BDSX 4
- Target Price
- IVCB N/A
- BDSX $3.08
- AVG Volume (30 Days)
- IVCB 41.7K
- BDSX 255.3K
- Earning Date
- IVCB 01-01-0001
- BDSX 11-05-2024
- Dividend Yield
- IVCB N/A
- BDSX N/A
- EPS Growth
- IVCB N/A
- BDSX N/A
- EPS
- IVCB 0.22
- BDSX N/A
- Revenue
- IVCB N/A
- BDSX $60,902,000.00
- Revenue This Year
- IVCB N/A
- BDSX $48.06
- Revenue Next Year
- IVCB N/A
- BDSX $29.97
- P/E Ratio
- IVCB $52.92
- BDSX N/A
- Revenue Growth
- IVCB N/A
- BDSX 46.25
- 52 Week Low
- IVCB $10.91
- BDSX $1.15
- 52 Week High
- IVCB $12.16
- BDSX $2.21
- Technical
- Relative Strength Index (RSI)
- IVCB 68.30
- BDSX 42.54
- Support Level
- IVCB $11.73
- BDSX $1.59
- Resistance Level
- IVCB $11.85
- BDSX $1.72
- Average True Range (ATR)
- IVCB 0.02
- BDSX 0.06
- MACD
- IVCB -0.01
- BDSX -0.01
- Stochastic Oscillator
- IVCB 60.00
- BDSX 29.17
About IVCB Investcorp Europe Acquisition Corp I
Investcorp Europe Acquisition Corp I is a blank check company.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.